

Journal Pre-proof

Impact of Communication on First Treatment Decisions in People with Relapsing-Remitting Multiple Sclerosis

Ana Manzano (Funding acquisition) (Project administration) (Data curation) (Writing - original draft) (Writing - review and editing), Ieva Eskytė (Data curation) (Formal analysis) (Investigation) (Methodology) (Writing - review and editing), Helen L. Ford (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), Hilary Bekker (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), Barbara Potrata (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), Jeremy Chataway (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), Klaus Schmierer (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), George Pepper (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing), David Meads (Conceptualization) (Methodology) (Writing - review and editing), Edward JD Webb (Methodology) (Writing - review and editing), Sue H Pavitt (Conceptualization) (Funding acquisition) (Methodology) (Writing - review and editing)

PII: S0738-3991(20)30280-9

DOI: <https://doi.org/10.1016/j.pec.2020.05.014>

Reference: PEC 6625

To appear in: *Patient Education and Counseling*

Received Date: 16 December 2019

Revised Date: 5 May 2020

Accepted Date: 11 May 2020

Please cite this article as: Manzano A, Eskyté I, Ford HL, Bekker H, Potrata B, Chataway J, Schmierer K, Pepper G, Meads D, Webb EJ, Pavitt SH, Impact of Communication on First Treatment Decisions in People with Relapsing-Remitting Multiple Sclerosis, *Patient Education and Counseling* (2020), doi: <https://doi.org/10.1016/j.pec.2020.05.014>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

Title page

Title: Impact of Communication on First Treatment Decisions in People with Relapsing-Remitting Multiple Sclerosis

Authors' names and affiliations:

Manzano, Ana^a; Eskyté, Ieva^b; Ford, Helen L^c; Bekker, Hilary^d; Potrata, Barbara^e; Chataway, Jeremy^f; Schmierer, Klaus^g; Pepper, George^h; Meads, David^d; Webb, Edward JD^d; Pavitt, Sue Hⁱ

^aSchool of Sociology & Social Policy, University of Leeds, Leeds, United Kingdom

^b School of Law, University of Leeds, Leeds, United Kingdom

^cLeeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

^dLeeds Institute for Health Science, University of Leeds, Leeds, United Kingdom

^eIndependent Consultant, Rotterdam, The Netherlands

^fDepartment of Neuroinflammation, UCL Institute of Neurology, University College London, London, United Kingdom

^gBlizard Institute (Neuroscience), Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom

^hShift.ms, Leeds, United Kingdom

ⁱSchool of Dentistry, University of Leeds, Leeds, United Kingdom

Corresponding author: Dr Ana Manzano, School of Sociology & Social Policy, Room 11.20 Social Sciences Building, University of Leeds, Leeds LS2 9JT, United Kingdom

Email address: a.manzano@leeds.ac.uk

Telephone/FAX: 00441133431290

Highlights

- Multiple new treatments are available for relapsing remitting multiple sclerosis
- Knowledge of disease, impact and prognosis is insufficient to make first choices
- Doctors and patients use different filtering mechanisms in decisions
- Clinical and psycho-social factors are important for patients in decisions
- Patient decision aids should consider first and consecutive decisions

Abstract

Objective: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for people with relapsing-remitting multiple sclerosis (pwRRMS). A challenge for services is how to support DMT decisions with changing clinical evidence, and differing treatment goals. This article investigates how pwRRMS weigh up the pros and cons of DMTs by examining how communication at the point of diagnosis is related to DMT decisions.

Methods: 30 semi-structured interviews with pwRRMS in England were conducted using a theoretical purposive sampling strategy and analysed using the thematic approach to answer: How does communication about RRMS during diagnosis influence decisions about when and which DMT to choose?

Results: Three meta-themes were identified: a) communication context; b) delayed communication and hope for people with “non-active” RRMS at diagnosis; c) people

with “active” RRMS at diagnosis: Conflated, generic, selective and simplified information

Conclusion: At the time of diagnosis, patient–physician interactions are characterised by emotions and information complexity. Clinical, social and psychological DMT filtering mechanisms are activated during first decisions. Personalised evidence is needed to make informed decisions.

Practice Implications: Patient decision aids should consider first and consecutive decisions and should not encourage a false sense of large choices that could add to decision anxiety.

Keywords

Multiple sclerosis

Relapsing-remitting multiple sclerosis

Disease-modifying therapy

Treatment decision-making

Diagnosis communication

Qualitative research

Shared decision-making

Patient perspective

Impact of Communication on First Treatment Decisions in People with Relapsing-Remitting Multiple Sclerosis

1. Introduction

Rapid advances in brain imaging and Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape in the diagnosis, treatment and care for people with relapsing-remitting multiple sclerosis (pwRRMS) [1, 2]. These advances mean a) more people are diagnosed with RRMS earlier in their lifespan; b) more treatments are available to manage symptoms and modify disease mechanisms; c) decision-making about how best to manage RRMS to fit in with people's lives is more complex [3] with immature evidence on the long-term consequences of DMTs [4, 5] and on effectiveness of treatment strategies (induction versus escalation) [6].

A challenge for services is how to best support people's management of their RRMS with changing clinical evidence and disease state, and differing goals for treatment planning. Evidence suggests patients do not receive adequate information from health care providers about DMTs [7] with advocacy groups requesting resources such as decisions aids for guidance [8]. Physicians' competency to communicate DMTs risks and benefits needs support [9]. Few studies have assessed patient-involvement interventions in MS care [10], and it is unclear how well usual practice meets these complex communication needs [11].

This article presents findings from a study aiming to investigate how pwRRMS weigh up the pros and cons of DMTs. We examine how communication at the point of diagnosis is related to DMT decisions. However, during pwRRMS' disease and treatment course, experiences of communication change. How these changes impact future treatment decisions is described elsewhere [12].

2. Methods

Little is known about DMT decision-making from the perspective of pwRRMS and, qualitative methods are recommended for exploring experiences, meaning and perspectives from the standpoint of the participants [13, 14]. A qualitative study of 30 semi-structured interviews with pwRRMS was performed to obtain in-depth understanding of people's experiences of choosing DMTs from when they were first diagnosed until the day of the interview. This includes identification of the main factors in starting, stopping, or switching DMT, which ones they prefer and why. In this paper we report findings on reasons to start and which ones to choose as their first DMT sometimes -but not always- shortly after diagnosis. This qualitative study was part of a project to develop a patient centre decision aid [15], which included evidence of stakeholders needs identified through systematic reviews [16. 17], interview study, and surveys using discrete choice experiment methods.

Participant eligibility criteria were: Clinician confirmed diagnosis of RRMS; aged 18+; written informed consent. We asked MS specialist neurologists in a MS referral centre in a large teaching hospital in the north of England (United Kingdom) to identify people meeting our study criteria. Patients were approached by a research nurse and once consent was obtained, they were contacted by a qualitative researcher (IE) who arranged a convenient place and time for the interview. There were 42 patients identified, 30 took part, nine declined to participate due to logistical issues (work commitments or lifestyle); and we were unable to contact three people. A theoretical purposive sampling strategy [18] was used to obtain a varied sample in

terms of DMT experience, in that we sought participants with diverse experiences of taking DMT (treatment naïve, experience with specific DMTs, people who decided to switch or stop DMTs), since these categories had been identified as relevant for the decision-making process in the literature. Even though analysis was guided by this knowledge, it was open to identify any potential new and emerging themes. For example, after analysing data from the first ten interviews, significant factors in DMT decision-making were identified that drove subsequent recruitment eligibility criteria to further consolidate our initial findings: women of fertile age; experience with DMTs with risk of progressive multifocal leukoencephalopathy (PML)¹; within one year of diagnosis; decided not to start DMT at the time of study entry; in full-time employment.

Interviews lasting between 45-90 min were conducted by an experienced qualitative researcher (IE) and were face to face (n=22) -in the participants' homes or their preferred venue (public space, private room in the hospital, etc.), or by phone (n=8) (Table 1). Topic guides (Table 2) were used which were informed by a systematic review [17], a critical interpretive synthesis [16], three focus groups (FG) and one dyadic interview [19] with pwRRMS. Two of the FG (n=7 and n=5) were with health care staff, including MS nurses and neurologists one small FG with pwRRMS (n=3).

[Insert Table 1 here]

Interviews were audio-recorded with participants' permission and all data was safely stored and anonymised, transcribed verbatim and analysed using a thematic analytical strategy [20] consisting of four interconnected steps:

¹ A life-threatening viral disease.

a) One qualitative researcher (IE) read verbatim transcripts to identify initial themes, guided by a flexible coding strategy based on our previous work. b) Detailed sub-categories to illustrate these themes were created and coded using NVivo (©QSR) International qualitative analysis software by IE, AM. c) These sub-themes were grouped into three broader categories or meta themes. This was done- by cross-referencing individual accounts with the entire data set and the rest of the themes. d) Meta-themes were refined through regular discussions with the wider research team (BP, HB, HF, SP), which included a pwRRMS (GP). The aim of the analysis strategy was to understand what is important in making decisions about treatments and when to start by examining: How does communication about RRMS during the diagnosis influence decisions about when and which DMT to choose?

Ethical approval was obtained from the NHS Health Research Authority (IRAS: 199646).

[Insert Table 2 here]

3. Results

Three meta-themes were identified: communication context; “non-active” RRMS at diagnosis; and active RRMS at diagnosis.

3.1 The Communication Context: Emotions, Clinical Pathways and Evidence

People’s experiences of the confirmation of diagnosis were heterogeneous, but there was a clear homogenous pattern in post-diagnosis emotional state: distress, shock,

anger, stigma, sadness and fear. There was also relief for some, which relates to ending uncertainty caused by delayed diagnosis [21-23], often with previous misdiagnoses including neurological, psychiatric and non-MS related eye disorders. People often related their emotional states to their choices about starting treatment. Adaline (aged 34) was informed of the diagnosis over the phone six years ago:

“Not starting treatment was probably partly to do with the fact I didn’t want to accept I had MS. That’s a massive thing when you first get diagnosed cause when I was first diagnosed I even heard them wrong on the phone. I heard that I didn’t have MS and that everything was wonderful but actually they were telling me that I did have MS. I completely heard something different. It just seemed a bit too real and I think I just didn’t wanna go on treatment.”

Within this emotional context, several incidents of ineffective practice in diagnosis communication were reported, with people having to ‘guess’ they had MS, being told over the phone, or finding out in referral letters. This was not the case for all participants with some recalling more effective communication practices. Although the possibility of recall bias should be taken into consideration, at the point of diagnosis people often reported limited in-depth conversations about RRMS, which were sometimes delayed until follow-up appointments. These experiences were equally observed in people diagnosed decades ago and recently. Time gaps between diagnosis and follow-up appointments magnified negative emotions about RRMS and clinical pathways. Eleonore (age 27) was diagnosed three months before the interview:

“So somebody just told me I had MS and then told me you will have to wait three months to understand what it is, no booklet, nothing”

People employed their own strategies to find additional information about RRMS with mixed success. Information was pursued online with a small number of participants also paying privately for consultations. People felt overwhelmed by information but unable to trust or interpret it:

“A lot of people, when you get diagnosed, ‘well my friend’s got MS’, or, ‘I was reading the paper the other day and there was a story about this drug’...People are trying to be nice and give you positive stories but to a degree you are just overwhelmed with all this information.” (Sam, age 39)

RRMS heterogeneity and how this affected DMT efficacy evidence was clearly communicated to people. This uncertainty framed the decision-making process, as Debbie (age 32) who stayed without medication for ten years recalled:

“I find that uncertainty very difficult too, I found that a big part in deciding whether to take the drugs or not. Whether it was like taking a gamble of whether I’d be alright without it.”

Recently diagnosed people had the added complexity that in current clinical pathways, diagnosis and treatment decisions are closer and can coincide [24]. In England to be prescribed a DMT, people need to meet clinical eligibility criteria (Table 3). This process creates two distinct communication experiences: 1) People categorised as having “inactive” RRMS; 2) People categorised with active RRMS meeting funding criteria to initiate DMT immediately.

[Insert Table 3 here]

3.2 “Inactive” RRMS at Diagnosis: Delayed Communication and Hope

Standardized definitions for MS clinical courses were established in 1996, revised in 2013 [25, 26], and in England inform clinical guidelines [27] and funding eligibility criteria [28]. The Lublin revision considered disease “activity” frequency as a modifier of the basic clinical course phenotype in RRMS (Table 3) but these phenotypes remain contested. During their life, pwRRMS may experience different levels of disease activity, and neurologists cannot predict when or how these may happen. Neurologists working in England perceive National Institute for Health and Care Excellence (NICE) prescribing guidelines as mandatory [29] and people who do not have active RRMS are not-eligible for DMTs. In our study those who did not meet DMT funding criteria when they were first diagnosed experienced reduced and delayed communication about how RRMS transitions through different stages of activity.

The distinction between inactive/active RRMS implicitly contributed to the hope that not meeting funding eligibility criteria equated to a form of “non-RRMS” which prevented people from initiating conversations not only about DMTs but also about RRMS clinical course. The periods of time when people did not meet funding criteria varied between a few months and years or decades. Participants waited in the hope that their RRMS did not advance, but they all described some level of “disrupted normality” [30]. People often did not passively wait for RRMS to advance, using non-biochemical self-management strategies such as diets and exercise routines based on beliefs associated with decreasing stress and relapses.

The timeframe between the evidence of DMT eligibility (clinically relevant frequent relapses [2]) and this being brought to the attention of medical professionals is mainly dependent on patients self-reporting symptoms. People frequently entered an active RRMS phase without reporting new symptoms because of a combination of individual and institutional interrelated factors (Table 4). This can be illustrated by Elisa's (aged 33) case who stayed without treatment for four years. She only started on Natalizumab (immune blocking DMT, administer monthly in hospital) when her mobility significantly reduced:

"I didn't think I needed treatment because ... I didn't feel too bad. Like I say I went downhill quite quickly. But I didn't phone my nurse or owt like that because I didn't notice it as such with it being a gradual decline. But maybe if I'd have known a bit more."

[Insert Table 4 here]

Some people in this group interpreted not being eligible for treatment as a positive sign because they hoped that this meant that their RRMS was not advancing. Others, who often experienced a more intrusive "non-eligible" fluctuation during the waiting period explained that when they tried to initiate conversations about DMTs, often doctors were not "open to discuss treatment" just yet.

When criteria were met, this was interpreted as a sign of their RRMS advancing but also as an offer that could not be refused. Debbie (aged 32) who finally qualified after having two relapses ten years after diagnosis, summarised this:

"I thought now that the NICE guidelines were saying that I'd qualified, that made me think, 'Oh, I must be getting worse...to the point where they will do something

to help me'. And then I couldn't live with the not taking treatment and not knowing if I had taken the treatment, if I'd have been better."

In summary, people with "inactive" RRMS waited in fear of their RRMS advancing, but communication encounters about RRMS and DMTs were few and delayed.

Although a small proportion of pwRRMS continue to have inactive RRMS during their lifespan, the majority have fluctuating levels of activity (relapses and periods of remission) and will transition to secondary progressive MS [31].

3.3 "Active" RRMS at Diagnosis: Conflated, Generic, Selective and Simplified Information

People whose RRMS met disease activity funding eligibility criteria [2] at diagnosis mainly experienced communication about treatments conflated with diagnosis information. For some people, like Catrina (aged 38, diagnosed two years ago), DMT information was encountered unintentionally (in referral letters, leaflets, etc.) or intentionally (searching online) even before diagnosis disclosure:

"I'd been to see my neurologist with the funny eye thing and I was supposed to have a review appointment with someone else. And I got a letter from the hospital saying, 'You have been transferred across to Dr X clinic which is a DMT clinic'. I was like, 'what the hell's DMT?' So I looked up DMT on the internet and it was like, 'Oh, it's disease modifying therapy. Okay so it probably is MS then' [...]. So my next appointment will be telling me that, and discussing these therapies."

People in this group were confronted with the initial decision to take treatment and which one to take while the natural emotional responses to diagnosis were very raw and knowledge about RRMS very poor. This is significant because conversations about whether to start treatment cannot be disentangled from which DMTs are available to each person and this availability is also related to RRMS phases and disease prognosis.

In our sample, it was apparent that the new drug landscape for RRMS distinctly influenced communication practices, with a potential long list of DMTs being used during consultations (12 DMTs were available during data collection [15]).

Neurologists normally introduced DMTs generic information, with MS nurses often dedicating more time to discuss specific details. Sometimes neurologists presented the full list of drugs without grouping or categorising them, which added to the fear of making the wrong decision. In these situations, people instinctively categorised DMTs by mode of administration since this was the only treatment attribute they could relate to:

“To be honest there was probably too many [DMTs]. I remember the big pull out leaflet that had them all on, and it was just, baffling_really... I remember reading a table of pros and against, and it was quite confusing because there were too many. And some that were very similar in effectiveness. The percentages and side effects, a lot of them were very similar, but they might've been injecting daily, once a month an IV injection.” Suzie (aged 30, diagnosed seven years ago)

Often participants reported neurologists providing a narrow set of options informed by their clinical judgement around three criteria:

a) Clinical incompatibility with some of the DMTs on the list, assessed by medical history and blood test screening or likelihood of effectiveness. This discarding mechanism sometimes resulted in a significant reduction of available choices. For example, Alex (aged 50) who had been on Copaxone (daily self-injectable immune modulation DMT) for five years at the time of interview explained how he was only offered two DMTs:

*“They looked at the blood test and said, ‘there are two possibilities for you’.
‘This is one and this is the other’.”*

b) Treatment approach and funding. Some DMTs were excluded at the point of diagnosis because *“you are not that bad yet”*. For example, only people categorised as having rapidly-evolving severe RRMS were offered immune reconstitution and immune blocking drugs, with the rest being presented with a reduced list of mainly immune modulation DMTs [32] (Table 5).

[Insert Table 5 here]

The conflation of treatment approach and funding seemed to generate feelings of privilege to the point that it seemed “immoral” to reject a DMT offer:

“I was lucky then that I was offered this treatment [Interferon, self-injectable immune modulation DMT] cause not everybody does. When I think back, that was why I did it, cause part of me partly felt, ‘if I don’t do it now I’ll not get the opportunity again’. Especially if I don’t have a relapse within a year cause that seemed to be criteria. Or you had to have so many relapses within a set period.”

(Rosa, aged 51, diagnosed three years ago).

c) **Clinical judgement and/or neurologist preference** were perceived as influencing the DMT offered. People often referred to the DMT “the doctor wanted me to take” or just said “they have put me on this treatment”. These preferences were mostly presented using simplified and sometimes simplistic explanations about risk and efficiency rates, as Tom (aged 44) explained:

“The choice was presented to me as a recommendation that I was free to disagree with. But the way in which it was presented, it was: ‘There’s Interferon [self-injectable] which reduces relapse rates by a third. And then there’s this neuro drug called Dimethyl Fumarate [tablet] which reduces relapse rates by about a half and you don’t have to have injections.’”

Incidents of people disagreeing with recommendations were scarce but present. When people chose a different DMT than the one recommended, this choice was respected. Tamara (aged 22) chose Alemtuzumab (immune reconstitution DMT, two infusions in hospital, one over five days, and another one, a year later over three days) as her first DMT:

“My doctor actually tried to convince me to go on the Natalizumab (infusion at hospital, one half a day every four weeks). He said a lot of his patients who are on Natalizumab would never ever choose anything else. And I was like, ‘No, I’ve made my decision’. Please don’t try and change it now”.

Participants acknowledged and often welcomed the need to have neurologists filtering options to support decisions given the uncertain and complex evidence. However, some filtering mechanisms, seemed to be informed by staff assumptions about DMT availability (funding criteria) and clinician personal preference.

People reflected on their reasons to start treatment which were mainly clinical (effectiveness) after having a relapse. People activated their own filtering mechanisms to choose which DMTs to take. These included a combination of social incompatibility (work, childcare), psychological factors (fears) with mode of administration and possible side effects. Suzie (aged 30) described how she chose her first DMT (Interferon, self-injectable) after rejecting Natalizumab (administered in hospital) because it was incompatible with childcare:

“I remember thinking that most of them had a similar percentage of success rate, so for me I suppose clinically that was all that really mattered. The side effects, there were good and bad to each of them. For me, it was more my personal life, like how safe are they around the children.”

To be able to rule out a DMT, people needed information so they could be evaluated with their own social and personal values rather than attributes of treatments assumed to be important for their effectiveness. As one of our participants (Chandler, aged 27) noted, people are told “this will happen” rather than having meaningful conversations about how DMTs attributes could impact in their life: “this will happen, how do you think this will affect you?”

4. Discussion and Conclusion

4.1 Discussion

This article illustrates how the growing complexity of RRMS diagnosis, treatment [33] and prognosis communication impacts people's ability to make meaningful first decisions about DMT. These decisions are unique and different from those taken later on in the disease course about switching to a different DMT [12].

Despite the significant increase of DMT availability, uncertainty about effectiveness remained common [34]. The natural emotional state post RRMS diagnosis [9, 35, 36] was exacerbated by clinical pathways characterised by few, short, diverted, delayed, selective and generic communication encounters. On the whole, people's knowledge needs about RRMS were not met and these are intrinsically related to DMT decisions. Patient–physician interactions at the time of diagnosis are characterised by stigma and fear, and information complexity. Disease course uncertainty and treatment benefits and risks add a greater emotional dimension. Within this context, quantity and quality of conversations were often perceived by pwRRMS as insufficient with information not being presented in a way that people could meaningfully interpret. These findings highlight the importance of physician communication when delivering diagnosis news, and how this is related to discussing prognosis and negotiating first treatment decisions.

Early treatment is now the recommended approach in RRMS [1, 37]. Too often, however, the necessary understanding of the disease impact and prognosis is not present in order to make informed choices. Physicians filtering mechanisms to support decisions were a mix of clinical and funding factors but patients filtered choices using a more complex combination of clinical and psycho-social factors.

Furthermore, in RRMS, the definition of individual prognosis is problematic [33] but clinical and national funding criteria, though not static, are often categorised as clear cut. In England, the distinction between inactive and active RMS influenced the pwRRMS communication experience, creating two distinct groups based on disease activity, while the categorisation of what counts as activity is often based on patients reporting it. In our study, established clinical pathways to monitor activity in those who are not taking DMTs seemed to be lacking.

4.2 Conclusion

This study demonstrated how both pwRRMS and clinicians used different filtering mechanisms to reduce the number of DMTs available to them during the decision-making process. The limitations of this study are that it is based on people's recall of communication, which is not always an accurate reflection of the information given during diagnosis and decision-making. However, it indicates that there is a consistent theme around decision conflict that is sustained over time, and suggests that more support is needed to encourage discussions along care pathways.

4.3 Practice implications

Decision aids can be helpful in a) providing a memory prompt, b) presenting all options and consequences neutrally, c) guiding people to think about how to cope with the fluctuating and dynamic nature of MS, d) categorising facts about MS and treatment options in a way that is cognitively easier to assimilate in emotional situations, and e) enabling informed conversations with the clinical team to agree on choices that are best for pwRRMS at that time, but may change [15]. However,

patient decision aids should allow for different types of decisions (first and consecutive) and should not encourage a false sense of large choices that could only add to decision anxiety. Evidence must be individualised for the patient [38] so they can personalise it and make informed decisions. This requires a strong clinician-patient relationship, which includes finding out what matters to people while allowing clinicians to exercise expert judgement. However, despite the institutional promotion of patient choice [39], optimal decisions require optimal circumstances and current clinical pathways and mechanical funding rules constrain this relationship and do not always encourage timely dialogue.

Declaration of Conflicting Interests

JC has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (NIHR); UK Multiple Sclerosis Society and National Multiple Sclerosis Society. In the last three years, he has been a local principal investigator for trials in multiple sclerosis funded by Receptos, Novartis and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in Advisory Boards/consultancy for Roche, Merck, MedDay, Biogen and Celgene.

HLF has received research support from the NIHR Health Technology Assessment Programme and the UK MS Society. In the last three years she has received speaker honoraria and/or served on advisory boards from Merck Serono, Novartis,

Teva and Sanofi-Genzyme and support to attend educational meetings from Biogen Idec.

KS is a Member of MAGNIFY-MS steering committee and MS Global Advisor Network (Merck).

Speaking honoraria from, and/or served in an advisory role for, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva.

Remuneration for teaching activities from EXCEMED, MedScape, MS Academy.

Supported for attendance of meetings by Merck, Novartis, Roche.

Research support from Barts Charity, Lipomed, Merck, Morris-Saady Charitable Trust, National Institute for Health Research, Medical Research Council, MS Society of Great Britain & Northern Ireland and US National MS Society

CRedit roles

AM: Funding acquisition; Project administration; Data curation; Formal analysis; Methodology; Roles/Writing - original draft; Writing - review & editing.

IE: Data curation; Formal analysis; Investigation; Methodology; Writing - review & editing

HF: Conceptualization; Funding acquisition; Methodology; Writing - review & editing

HB: Conceptualization; Funding acquisition; Methodology; Writing - review & editing

BP: Conceptualization; Funding acquisition Methodology Writing - review & editing

JC: Conceptualization; Funding acquisition Methodology Writing - review & editing

KS: Conceptualization; Funding acquisition; Methodology; Writing - review & editing

GP: Conceptualization; Funding acquisition; Methodology; Writing - review & editing

DM: Conceptualization; Methodology; Writing - review & editing

EW: Methodology; Writing - review & editing

SP: Conceptualization; Funding acquisition; Methodology; Writing - review & editing

Acknowledgements

This work was supported by the Multiple Sclerosis Society (UK) [award number: 30] and by the National Institute for Health Research (NIHR) infrastructure at Leeds (UK). The views expressed are those of the author(s) and not necessarily those of the MS Society, the NHS, the NIHR or the Department of Health.

Journal Pre-proof

References

1. A. J. Thompson, B.L Banwell, F. Barkhof, W.M. Carroll, T. Coetzee, G. Comi, J. Correale, F. Fazekas, , M. Filippi., M.S Freedman and K. Fujihara, Diagnosis of multiple sclerosis: 2017 revisions of the Mcdonald criteria, *The Lancet Neurology* 17 (2018) 162-173, [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2).
2. National Institute for Health and Care Excellence, Disease-modifying therapies for multiple sclerosis, <http://pathways.nice.org.uk/pathways/multiple-sclerosis>, 2020 (accessed 20 March 2020).
3. C. Bischoff, H. Schreiber, A. Bergmann, Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment, *J. Neurol* 259 (2012) 2347-2353, <https://doi.org/10.1007/s00415-012-6499-1>.
4. T. Ziemssen, K. Thomas, Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world, *Ther. Adv. Neurol. Diso.*10 (2017) 343-359, <https://doi.org/10.1177/1756285617722706>.
5. University of California, San Francisco MS Epic Team: B. A. Cree, P.A. Gourraud, J.R. Oksenberg, C. Bevan, E. Crabtree-Hartman, J.M. Gelfand, D.S. Goodin, J. Graves, A.J. Green, E. Mowry, Long-term evolution of multiple sclerosis disability in the treatment era, *Ann. Neurol.* 80 (2016) 499-510, <https://doi.org/10.1002/ana.24747>.

6. G. Fenu, L. Loreface, F. Frau , G.C. Coghe , M.G. Marrosu, E. Cocco, Induction and escalation therapies in multiple sclerosis, *Antiinflamm. Antiallergy Agents Med. Chem.* 14 (2015) 26-34, <https://doi.org/10.2174/1871523014666150504122220>.
7. C. Heesen, J. Kasper, S. Köpke, T. Richter, J. Segal, I. Mühlhauser, Informed shared decision making in multiple sclerosis—inevitable or impossible?, *J Neurol. Sci.* 259 (2007) 109-117, <https://doi.org/10.1016/j.jns.2006.05.074>.
8. MS Society. Treat me right. <https://www.mssociety.org.uk/get-involved/campaign-with-us/treat-me-right> , 2018 (accessed 20 March 2020).
9. A.Solari, Effective communication at the point of multiple sclerosis diagnosis, *Mult. Scler. J.* 20 (2014) 309-402, <https://doi.org/10.1177/135245851452306>.
10. D. Stacey, F. Légaré, N.F. Col, C.L Bennett., M.J. Barry, K.B. Eden., M. Holmes-Rovner, H. Llewellyn-Thomas, A. Lyddiatt, R. Thomson, L. Trevena., Decision aids for people facing health treatment or screening decisions, *Cochrane Database Syst. Rev.* CD001431 (2014) 1-292, <https://doi.org/10.1002/14651858.CD001431.pub5>.
11. A.M. O'Connor, F. Légaré, D. Stacey Risk communication in practice: the contribution of decision aids, *Brit. Med. J* 327 (2003) 736-740, <https://doi.org/10.1136/bmj.327.7417.736>.
12. [Anonymised], Treatment switching decision-making in relapsing-remitting multiple sclerosis. A qualitative study [Unpublished] 2020.
13. Hammarberg, K., Kirkman, M. and de Lacey, S., Qualitative research methods: when to use them and how to judge them. *Hum. Rep.* 31(2016) 498-501, <https://doi.org/10.1093/humrep/dev334>.

14. Yardley, L., Dilemmas in qualitative health research, *Psychol. Health*, 15(2000) 215-228, <https://doi.org/10.1080/08870440008400302>.
15. [Anonymised]. Treatment Decision Making and Relapsing Remitting Multiple Sclerosis. The CRIMSON Project Decision Aid Booklet. (2019). University of Leeds, https://crimson.leeds.ac.uk/wp-content/uploads/sites/51/2019/12/UOL169_CRIMSON-A4-Brochure_WEB.pdf (accessed 20 March 2020).
16. [Anonymised], Understanding treatment decisions from the perspective of People with Relapsing Remitting Multiple Sclerosis: A critical interpretive synthesis, *Mult. Scler. Relat. Disor.* 27 (2019) 370-377, <https://doi.org/10.1016/j.msard.2018.11.016>.
17. [Anonymised], A systematic review of discrete-choice experiments and conjoint analysis studies in people with multiple sclerosis, *PATIENT* 11 (2018), 391-402, <https://doi.org/10.1007/s40271-017-0296-y>.
18. O.C. Robinson, Sampling in interview-based qualitative research: A theoretical and practical guide, *Qual. Res. Psychol.* 11(2014) 24-41, <https://doi.org/10.1080/14780887.2013.801543>.
19. D.L. Morgan, J. Ataie, P. Carder, K. Hoffman, Introducing dyadic interviews as a method for collecting qualitative data, *Qual. Health. Res.* 23 (2013), 1276-1284, <https://doi.org/10.1177/1049732313501889>.
20. J. Ritchie, L. Spencer, Qualitative data analysis for applied policy research. The qualitative researcher's companion, in: A. Bryman, B. Burgess. (Eds.), *Analyzing Qualitative Data*, Routledge, London, 2002, 305-329.
21. L. Barin, C.P. Kamm, A. Salmen, H. Dressel, P. Calabrese, C. Pot., S. Schippling, C. Gobbi, S. Müller, A. Chan, S. Rodgers, How do patients enter

- the healthcare system after the first onset of multiple sclerosis symptoms?
The influence of setting and physician specialty on speed of diagnosis, *Mult. Scler. J.* 26 (2020), 1-12, <https://doi.org/10.1177/1352458518823955>.
22. O. Fernández, V. Fernández, T. Arbizu, G. Izquierdo, I. Bosca, R. Arroyo, J. G. Merino, E. De Ramón, Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study), *J. Neurol.* 257(2010) 1500-1507, <https://doi.org/10.1007/s00415-010-5560-1>.
23. A. J. Solomon, J. R. Corboy, The tension between early diagnosis and misdiagnosis of multiple sclerosis, *Nat. Rev. Neurol.* 13 (2017) 567-572, <https://doi.org/10.1038/nrneurol.2017.106>.
24. C. Heesen, .A. Giordano, J. Kasper, S. Kopke, Decisions on multiple sclerosis immunotherapy: New treatment complexities urge patient engagement, *J. Neurol. Sci.* 306 (2010) 192-197, <https://doi.org/10.1016/j.jns.2010.09.012>.
25. F. D. Lublin, S.C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey, *Neurol.* 46 (1996) 907-911, <https://doi.org/10.1212/WNL.46.4.907>.
26. F. D. Lublin, S.C. Reingold, J.A. Cohen, G.R. Cutter, P.S. Sørensen, A.J. Thompson, J.S. Wolinsky, L.C. Balcer, B. Banwell, F. Barkhof, B. Bebo, Defining the clinical course of multiple sclerosis: the 2013 revisions, *Neurol.* 83 (2014) 278-286, <https://doi.org/10.1212/WNL.0000000000000560>.
27. N. Scolding, D. Barnes, S. Cader, J. Chataway, A. Chaudhuri, A. Coles, G. Giovannoni, D. Miller, W. Rashid, K. Schmierer, A. Shehu, Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis, *Pract. Neurol.* 15 (2015) 273-279, <http://dx.doi.org/10.1136/practneurol-2015-001139>.

28. NHS England, Recommendations for an NHS England algorithm to use disease-modifying drugs to treat multiple sclerosis, <https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf>, 2017 (accessed 20 March 2020).
29. E. Cameron, D. Rog, G. McDonnell, J. Overell, O. Pearson, D.P. French, Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study, *Mult. Scler. Relat. Disor.* 27 (2019) 378-382, <https://doi.org/10.1016/j.msard.2018.11.023>.
30. T, Sanderson, M. Calnan, M. Morris, P. Richards, S. Hewlett, Shifting normalities: interactions of changing conceptions of a normal life and the normalisation of symptoms in rheumatoid arthritis, *Sociol. Health Illn.* 33 (2011) 618-633, <https://doi.org/10.1111/j.1467-9566.2010.01305.x>.
31. A. Compston, A. Coles, Multiple sclerosis, *Lancet*, 372 (2008) 1502-1507, [https://doi.org/10.1016/S0140-6736\(08\)61620-7](https://doi.org/10.1016/S0140-6736(08)61620-7).
32. D. Baker, M. Marta, G. Pryce, G. Giovannoni, K. Schmierer, Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis, *EBioMed* 16 (2017) 41-50, <https://doi.org/10.1016/j.ebiom.2017.01.042>.
33. G. Comi, M. Radaelli, P. S. Sørensen, Evolving concepts in the treatment of relapsing multiple sclerosis, *Lancet* 389 (2017) 1347-1356, [https://doi.org/10.1016/S0140-6736\(16\)32388-1](https://doi.org/10.1016/S0140-6736(16)32388-1).
34. M. Trojano, M. Tintore, X. Montalban, X., J. Hillert, T. Kalincik, P. Iaffaldano, T. Spelman, M.P. Sormani, H. Butzkueven, Treatment decisions in multiple

- sclerosis—insights from real-world observational studies, *Nat. Rev. Neurol.* 13 (2017) 105-118, <https://doi.org/10.1038/hrneurol.2016.188>.
35. H. Livneh, R.F. Antonak, Reactions to disability: An empirical investigation of their nature and structure, *J. App. Rehabil. Cos.*, 21 (1990) 13-21. <https://doi.org/10.1891/0047-2220.21.4.13>.
36. R.F. Antonak, H. Livneh, Psychosocial adaptation to disability and its investigation among persons with multiple sclerosis, *Soc. Sci. Med.* 40 (1995) 1099-1108. [https://doi.org/10.1016/0277-9536\(94\)00167-R](https://doi.org/10.1016/0277-9536(94)00167-R).
37. M.J. Barry, S. Edgman-Levitan, Shared decision making—the pinnacle of patient-centered care, *N. Eng. J. Med.* 366 (2012) 780-781, <https://doi.org/10.1056/NEJMp1109283>.
38. T. Greenhalgh., J. Howick, N. Maskrey, Evidence based medicine: a movement in crisis?, *Brit. Med. J.*, 348 (2014) 1-7, <https://doi.org/10.1136/bmj.g3725>.
39. Department of Health, The NHS Choice Framework: what choices are available to me in the NHS? <https://www.gov.uk/government/publications/the-nhs-choice-framework/the-nhs-choice-framework-what-choices-are-available-to-me-in-the-nhs>, 2020 (accessed 20 March 2020).

Tables

Table 1. Participant Demographic information

	Total Number of Participants = 30			
GENDER	FEMALE	MALE		
	22	8		
ETHNICITY	WHITE	BLACK BRITISH (CARIBBEAN)	ASIAN BRITISH (PAKISTANI)	
	28	1	1	
AGE	18-25	26-30	31-45	46-56
	2	10	12	6
AGE AT DIAGNOSIS	15-25	26-30	31-45	46-56
	12	7	8	3
DISEASE DURATION	< 12 MONTHS	1-5 YEARS	6-10 YEARS	11-20 YEARS
	4	10	11	5
DMT NUMBER	0 DMT	1 DMT	2 DMT	3 OR MORE DMT
	3	11	8	8

Table 3 Interview Topic Guide

INFORMATION AREA	QUESTIONS & PROMPTS
Introduction to the diagnosis	<ul style="list-style-type: none"> - Understanding MS: First MS symptoms; first relapse; first contact with medics - Were you diagnosed with MS straight away or were you diagnosed with something else? - What were your first thoughts when you found out that it was MS? Did you know anything about MS? - What do you know about MS now? How did you find out/ learn about MS? - What did your clinician tell you about MS? - How do you feel as a person, as you about having MS?
Introduction to treatment	<ul style="list-style-type: none"> - Could you please tell me about your first chat with the clinician about the treatment? What was the clinician's idea? - How were available treatments explained to you? Which aspects of the available treatments were explained to you? - What were your first thoughts when you heard all this information? - What was the most important/scary/ relieving for you? Was this information enough to make a decision? - Were you suggested with a specific treatment or were you advised to choose? - Did you make the decision immediately or you decided/ had to wait? Why? - At what point did this discussion happen? Immediately after the diagnosis? After how long? - Very often MS nurse is closely involved in treatment introduction and selection. Was this helpful? How did you find this experience? - How did you find the decision making process? Was it easy to decide?
DMT characteristics and decision making	<ul style="list-style-type: none"> - You are currently considering a possibility to start or have recently decided to start treatment. What factors were most important for you in making this decision? Why these particular factors? - How much information did you have about the way the treatment works and its benefits? How did you find out about it? Did your position or feeling about it change? How? - When it comes to the effect of or the way DMTs work, it is usually making relapses more frequent and more severe. How does this affect your progression in the future. What is more important for you at this stage? - How do you think, may your priorities change in the future? - Some people have relapses even though they are on treatment. How do you think, would you? - How would you describe an effective treatment? - How much information did you have about side effects and risks of your treatment? How did you find out about this? How were your thoughts when you found out all this? How did this effect your decision? - The majority of treatments have various side effects. What about your chosen treatment? How do you think about this? - What kind of side effects would you be willing and able to tolerate and to which would you be willing to accept? - Some treatments may cause additional illnesses like liver-dysfunction, kidney problems, etc. How do you think about this? As you may know, some treatments may cause severe side effects like blood clots, etc. Would you take risk and choose such kind of treatment if it would slow down illness progression? How would you go? If you need to choose what would you choose: more effective treatment or less effective treatment that has less side effects? - Do/ did you explore treatment options yourself? Where did you look for information? How did you make your choice? How? - As you know, DMTs are mainly in three forms: tablets, self-injections and infusions. Which do you prefer? If you need to choose, what would you choose: less effective treatment or more effective treatment that is in a format that you do not like? - Some DMTs require regular monitoring, like having your blood tested, meaning that you need to go to the hospital for a check-up. Would this have an impact on which medication you choose? How would you think about this? - What are your priorities or preferences for the treatment? What would be your top 3 priorities? What would be a realistically ideal DMT?

<p>Interaction with a clinicians and decision making</p>	<ul style="list-style-type: none"> - Did you discuss the things we have just discussed with your clinician? Did your prior deal with the situation? - If the neurologist advised you to start/ not start/ delay treatment, what reasons did h consultant or sought further medical advice to gain access to a specific DMT? - How do you think, the way that you clinician explain treatment options may influence - How would you describe communication experience with your clinician in general? DMT before you have started treatment? How were they addressed? Did you have that matter to you? - What staff characteristics are important, in your opinion, when they interact with the people say that often clinicians see illness and only then a person. What about your discussed and considered when deciding treatment? - What was your experience when communicating with MS nurse? When did you mee him? How was communication with MS nurse different from communication with a c deciding which treatment to choose? What in particular was helpful?
<p>Social support and decision making</p>	<ul style="list-style-type: none"> - Do your family members, friends or colleagues know about your MS? - Is anyone from your family or close environment involved in the decision making pro support? Do your and their positions match?
<p>General</p>	<ul style="list-style-type: none"> - How would you describe your attitude to treatment decisions in general? Do you pre family/ friends or make decisions on your own? Would you take any alternative or ac - How would you describe your life before and after the diagnosis? What have been th How do you manage the changes? Do you do anything to keep your life as it was be year; 5 years; 10 years? How do you think, does having MS may reshape these plan

Table 3: Activity phases of Relapsing Remitting Multiple Sclerosis

PHASE	CLINICAL INDICATORS
Stable ("inactive)	No new relapses in the last 12 months
Active	At least two relapses in the last 12-24 months
Highly active	New or ongoing relapses in the last 12 months, when taking a disease modifying treatment like Beta-interferon.
Rapidly evolving severe	At least 2 relapses in the previous year and at least 1 T1 gadolinium-enhancing lesion at baseline MRI

Source: NICE (2019) Disease-modifying therapies for multiple sclerosis.[2]

Journal Pre-proof

Table 4: Main factors preventing pwRRMs reporting new symptoms to MS team during the wait and see phase

MAIN FACTORS	
1.	Relapses are heterogeneous and there are knowledge gaps and there can be disagreement between pwRRMS and neurologists on what RRMS activity looks like.
2.	Newly diagnosed pwRRMS receive little information and had limited experiential knowledge about RRMS.
3.	There are scarce planned follow-up visits in clinical pathways for those who are not taking DMTs who can often have long-periods of time without contacting specialist MS staff.
4.	The presence of emotional barriers (guilt, regret, denial, failure) which are related to accepting that their “non-RRMS” has advanced to “RRMS” and that their non-biomedical strategies had failed to protect them from transitioning to the next RRMS stage.

Table 5: Type of Disease-Modifying Treatments [30] available in England at the time of data collection

GROUPS OF DMTS ACCORDING TO WHAT THEY TRY TO DO	WAY IN WHICH THE DMT WORKS	DMTS AVAILABLE IN THE UK
<p>Immune modulation options They change the strength of white cells in the immune system (lymphocytes).</p>	<p>The immune system is then less able to damage the nerves.</p>	<p>Beta-interferons, Copaxone, Dimethyl-fumarate, Teriflunomide</p>
<p>Immune reconstitution options They change the types and strength of white cells in the immune system (lymphocytes).</p>	<p>The immune system is then made up of a different number of cells which are less likely to damage the immune System.</p>	<p>Alemtuzumab, Cladribine, Ocrelizumab</p>
<p>Immune blocking options They can stop immune cells from getting out of the lymph nodes (Fingolimod) or from getting into the brain (Natalizumab).</p>	<p>This means there are fewer cells that can damage the nerves.</p>	<p>Fingolimod, Natalizumab,</p>